Leukotriene modifiers linked to neuropsychiatric symptoms

Leukotriene modifying drugs including montelukast (Singulair), zafirlukast (Accolate), and zileuton (Zyflo) have been associated with an increased risk of neuropsychiatric symptoms and should be discontinued in patients admitted with symptoms. Symptoms include agitation, aggression, hallucinations, depression, and suicidality (FDA site)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment